Kenneth T. Mills - Jun 24, 2021 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
President and CEO, Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Jun 24, 2021
Transactions value $
-$217,905
Form type
4
Date filed
6/28/2021, 04:18 PM
Next filing
Sep 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $16.9K +4.5K +1.6% $3.76* 285K Jun 24, 2021 Direct F1
transaction RGNX Common Stock Sale -$180K -4.5K -1.58% $40.02 281K Jun 24, 2021 Direct F1, F2
transaction RGNX Common Stock Options Exercise $5.64K +1.5K +0.53% $3.76* 282K Jun 25, 2021 Direct F1
transaction RGNX Common Stock Sale -$60.4K -1.5K -0.53% $40.25 281K Jun 25, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -4.5K -1.64% $0.00 271K Jun 24, 2021 Common Stock 4.5K $3.76 Direct F1, F3
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -1.5K -0.55% $0.00 269K Jun 25, 2021 Common Stock 1.5K $3.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.